Participant flow

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma · Source last updated 2015-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive 800mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

   id

   FG000

   title

   Arm I

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

All 34 participants were evaluable for the primary endpoint.

recruitment Details

Thirty-four participants were accrued between May 2007 and October 2008.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice